Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

A team of University of Kentucky Markey Cancer Center researchers has found the mechanism that grants prostate cancer ...

"It’s crucial that patients and their families know about this new option," said Dr. William Russell, an oncology radiologist ...

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...

Lenny Santoro credits NIH research with saving his life longer than doctor's expected. Duke Health's Dr. Daniel George warns ...

First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone and with other drug combinations. The FDA has approved the use of Gozellix, a ...

Yet, these PDE5i drugs (originally patented as Viagra, Cialis, and Levitra) remain the first and often only treatment offered ...

The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor ...

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

The antibody-drug conjugate FOR46 showed the strong potential of using CD46 as a new therapeutic target in metastatic ...

A newly expanded prostate cancer drug could bring new hope to patients with a common form of the disease. Novartis, a Switzerland-based pharmaceutical company, announced on March 28 that the U.S ...

breakthrough medication for patients with advanced prostate cancer that has spread to other parts of the body. The medication could be life-changing for many patients in Louisiana, where prostate ...